The in vitro effects of faropenem on lower respiratory tract pathogens isolated in the United Kingdom.
Faropenem is a new oral penem with a structure different from current beta-lactams including carbapenems. The susceptibility of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis to faropenem, a macrolide, a beta-lactam, a beta-lactam/beta-lactamase inhibitor combination and two fluoroquinolones was investigated. S. pneumoniae was the most susceptible of the three species to faropenem. The MIC(90)s of faropenem against M. catarrhalis and H. influenzae were 0.5 and 1 mg/l, respectively. They were similar to amoxiclav (MIC (90)s of 0.25 and 0.5 mg/l). The quinolones showed strong activity against H. influenzae. A cluster analysis of the activities of amoxycillin and faropenem demonstrated a direct relationship between the two antimicrobial agent's activities and resistance profiles against both S. pneumoniae and H. influenzae.
Walsh
F
F
Molecular Chemotherapy, Medical Microbiology, Medical School, University of Edinburgh, Teviot Place, EH8 9AG, Edinburgh, UK. fwalsh@staffmail.ed.ac.uk
Amyes
A K B
AK
Amyes
S G B
SG
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D006193:Haemophilus influenzae / Q000187:drug effects* / Q000302:isolation & purification; D007769:Lactams; D008826:Microbial Sensitivity Tests; D001936:Moraxella catarrhalis / Q000187:drug effects* / Q000302:isolation & purification; D012141:Respiratory Tract Infections / Q000382:microbiology*; D013296:Streptococcus pneumoniae / Q000187:drug effects* / Q000302:isolation & purification; D006113:United Kingdom; D047090:beta-Lactams
D000900:Anti-Bacterial Agents; D007769:Lactams; D047090:beta-Lactams; C107057:fropenem